Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Report

Vertex Pharmaceuticals delivered impressive financial results for Q4 2024, with total revenue reaching $2.91 billion, an increase of 16% compared to Q4 2023, and a record full-year revenue of $11.02 billion, up 12% from the previous year. This year's growth was primarily fueled by a robust performance in the cystic fibrosis (CF) sector, aided by the successful launch of the new medication ALYFTREK. Additionally, the newly approved JOURNAVX offers Vertex a solid entry into the non-opioid pain management market, potentially enhancing patient accessibility and addressing the opioid crisis. Management views this as a pivotal year for diversifying revenue streams and expanding patient reach.